Hints and tips:
Related Special Reports
Related Topics
...Gilead has worked with scientists at Accelerated Clinical Trials Ltd to develop a blood cancer treatment....
Millions of Paxlovid pills have gone unused as tight controls restrict access
...Instead, Isomorphic chose to sign deals with just two pharmaceutical companies....
...But until recently, many large pharmaceutical companies were reluctant to invest heavily in finding treatments after decades of failure....
...The virtue of putting private collections on public display is inculcated in Switzerland’s merchant class, the heirs to textile and pharmaceutical fortunes....
Shionogi chief warns companies are deserting the field to focus on more lucrative areas
...Thomas said she expected AlphaMissense to be used in healthcare as “a co-pilot for clinical scientists, flagging which variants they should be focusing on so that they can do their jobs more efficiently”...
Japan’s Eisai says it will not finalise Leqembi spending plans until government clarifies financial support
...It comes after decades during which many big pharmaceutical companies lost hope and cut investment in Alzheimer’s research....
...The US Food and Drug Administration in January approved lecanemab, a drug co-developed by Japanese drugmaker Eisai and US biotech Biogen, under an accelerated process....
...more than 10 per cent over the past five trading days while Shanghai Fosun Pharmaceutical added 7 per cent....
...Risk management Winner: Johnson & JohnsonOriginality: 8; Leadership: 9; Impact: 9; Total: 26The litigation team in Asia-Pacific designed a digital system for the pharmaceutical business to improve its management...
...Blackmores was established 91 years ago by Maurice Blackmore who co-founded one of the country’s first health stores in Brisbane in 1938....
...That’d be bad news for Hikma Pharmaceuticals (27.2 per cent). What about board chairs and their deputies?...
...That is a step up from current drugs that treat only symptoms: a landmark success in a desert strewn with pharmaceutical failures....
...Lecanemab, which was co-developed by Tokyo-based Eisai and US biotech Biogen, is a monoclonal antibody that acts by reducing the build-up of sticky plaques in the brain called beta-amyloid....
...Deutsche Bank has hired Perella Weinberg Partners’ Marie-Soazic Geffroy as global co-head of its financial institutions group, based in Paris....
Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing
...To navigate the pharmaceutical and regulatory landscape, Compass has recruited Kabir Nath, a new chief executive with a background at a large drugmaker, the Japanese company Otsuka....
...“We want [BioArctic] to be a fully-fledged pharmaceutical company: that is our ambition.”...
The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down
...Both Roche’s gantenerumab and lecanemab, co-developed by Eisai and Biogen, are monoclonal antibody treatments based on the hypothesis....
...Most Alzheimer’s drug candidates are not discovered by pharmaceutical companies but in academic labs and biotech businesses....
Japanese company refuses to rule out possibility treatment contributed to brain bleeds
Treatment is new weapon against mosquito-borne disease that kills 20,000 people a year
International Edition